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 Hepatocell�lar carcinoma �HCC�� is the fifth most 
freq�ent neoplasm worldwide�� b�t owing to the lack 
of effective treatment options�� represents the third 
leading ca�se of cancer death [�]. The only c�rative 
treatments for HCC are s�rgical resection or liver 
transplantation�� b�t mostly patients are s�ffering from 
advanced disease and are not candidates for s�rgery. 
To date�� systemic chemotherape�tic treatment is inef-
fective against HCC�� and no single dr�g or dr�g combi-
nation prolongs s�rvival [�]. Despite progress in early 
diagnosis�� the prognosis remains poor�� beca�se many 
HCC t�mors are discovered when the process is not 
amenable to s�rgery [�]. The common occ�rrence of 
�nderlying cirrhosis�� the presence of m�ltiple lesions 
within the liver�� the invasion of vital str�ct�res within 
the v. porta hepatis�� and the extension of the disease 
o�tside the liver freq�ently prevent s�rgery. In addition�� 
after resection�� there is a very high t�mor rec�rrence 
rate �abo�t �5% per year���� which limits c�rability and 
long-term s�rvival. Th�s�� when transplantation is not 
possible�� no good therape�tic options are available for 
HCC. It is therefore clear that there is an �rgent need 
to develop new approaches to treat HCC.
Highly efficient antigen presentation by antigen 
presenting cells �APCs�� is a req�isite for the develop-
ment of T-cell-mediated imm�nity in vitro and in vivo 
[�]. Increasing evidence s�pports the hypothesis that 
not all APCs have the same capacity to ind�ce and pro-
mote an imm�ne response. For example�� only dendritic 
cells �DCs�� have been shown to prime naive T-cells 
and to ind�ce memory T-cells to become effectors. 
For these reasons�� many investigators attempting to 
ind�ce imm�nity to viral [5�� 6] or t�mor antigens [��� 8] 
have foc�sed their attention on DCs. In these fields�� 
DCs have been �sed as cell�lar adj�vants to present 
antigen in vivo [��� ��]�� as APCs in vitro to determine 
imm�nocompetence�� and�� finally�� in experiments at-
tempting to define imm�nogenic peptides from viral 
[��]�� a�toimm�ne [��]�� and t�mor antigens [������].
Altho�gh highly efficient in their capacity to in-
d�ce T-cell imm�nity�� DCs have several significant 
drawbacks. First�� they are relatively rare in peripheral 
blood and are therefore �s�ally isolated from apher-
esis or marrow so�rces [�5]. Second�� DCs are not 
homogeneo�s b�t represent several pop�lations of 
f�nctionally disparate cell types�� incl�ding tolerogenic 
DCs [�6]. Third�� it is diffic�lt to expand DCs ex vivo 
from non-stem cell so�rces witho�t significant in vivo 
expansion with cytokines [��]. Finally�� all of the above 
approaches are laborio�s�� expensive�� and therefore 
presently restricted in their clinical applicability.
CD�� ligand �CD��L�� is a member of the t�mor 
necrosis factor family�� which is expressed on activated 
T-cells and binds to CD�� present on the membrane 
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of APCs [�8�� ��]. CD��-CD��L interaction plays a cr�-
cial role in the activation of APC and in the initiation of 
both h�moral and cell�lar imm�ne responses [�����]. 
Th�s�� gene transfer of CD��L has been proposed as an 
efficient means to treat malignancies. Sch�ltze et al. 
[��] and von Bergwelt-Baildon et al. [��] reported 
that peptide-loaded CD��-B are as effective as DCs in 
ind�cing a�tologo�s antigen-specific T-cell responses 
against viral and t�mor-associated antigens in vitro. 
Protein and retroviral loading of CD��-B has also been 
effective for T-cell stim�lation in vitro.
In this st�dy�� we propose t�mor total RNA-loaded�� 
CD��-activated B-cells �CD��-B�� as an alternative 
antigen-presenting cell vaccine with potent T-cell 
stim�latory capacity and the ability to be generated 
from a small vol�me of peripheral blood�� and demon-
strate that CD��-B can be transfected with total HCC 
cells RNA to generate specific cytotoxic T-lympho-
cytes �CTLs�� CD8+T-cells�� expansion and secretion 
of interferon-γ �IFN-γ��. F�rthermore�� the activated 
CD8+T-cells show a killing effect on HCC cells. These 
findings s�ggest that CD��-B/RNA technology can be 
�sed in HCC imm�notherapy. 
MATERIALS AND METHODS
Blood samples and cell lines. Blood sample and 
t�mor specimens were obtained from a patient with HCC 
diagnosed in clinics. The patient is 5� years old�� male�� 
and was examined by USG�� X-ray and AFP check. Periph-
eral blood monon�clear cells �PBMCs�� phlebotomized 
from the HCC patient were isolated by Ficoll centrif�ga-
tion. PBMCs phlebotomized from healthy donor was 
�sed as a control. Primary c�lt�red cell line was obtained 
from the HCC patient’s t�mor specimens.
Preparation of CD40-activated B-cells. To gen-
erate activated B-cells�� PBMCs were stim�lated with 
sCD�� ligand �sCD��L��. Briefly�� PBMCs were added at 
��6 cells/ml in B-cell medi�m�� consisting of RMPI �6�� 
s�pplemented with ��% fetal calf ser�m �FCS���� sCD��L 
�� μg/ml���� recombinant h�man interle�kin-� �rhIL-��� 
�� ng/ml���� and cyclosporine A ��.6�5 μg/ml; Novartis�� 
Switzerland��. After � days�� c�lt�red cells were replated 
in B-cell medi�m and then restim�lated with sCD��L and 
IL-� every � to 5 days �p to �� days�� and flow cytometry 
was performed as described below. After �� days of 
c�lt�ring�� CD��-B-cell pop�lations were more than ��%. 
Before �sed in following experiments�� Percoll density 
centrif�gation was performed to remove dead cells. 
Cryopreservation procedure. PBMCs or 
CD��-B-cells were frozen in cryot�bes at a concentra-
tion of ���� × ��6/ml in ��% FCS and ��% dimethyl-
s�lphoxide �DMSO�� �Sigma��. Cell s�spensions were 
slowly frozen at � °C for �� min�� then at ��� °C for 
�� min�� and overnight at �8� °C. Frozen cells were 
thawed q�ickly in a �� °C water bath�� followed by the 
addition of ��% FCS RMPI �6�� sol�tion. Next�� cells 
were centrif�ged and res�spended at �.5 × ��6/mL 
in ��% FCS RMPI �6�� sol�tion for �5 min to remove 
resid�al DMSO. Finally�� cells were washed once and 
res�spended in c�lt�re medi�m.
Immunophenotyping of CD40-B-cells. The 
monoclonal antibodies �PE��-conj�gated anti-CD8� 
and �PE��-conj�gated anti-CD86 �BD Bioscience�� 
Belgi�m�� were �sed for imm�nophenotyping of periph-
eral blood and CD��-B-cells. Non-reactive isotype-
matched antibodies �BD Bioscience�� Belgi�m�� were 
�sed as negative controls. On days ��� �� and ���� CD8� 
and CD86 were determined respectively by Flow Cy-
tometry Analysis System �FCAS��. The level of interle�-
kin-�� �IL-���� prod�ced by the c�lt�red CD��-B was 
meas�red �sing an enzyme-linked imm�nosorbent 
assay �ELISA�� �BioSo�rce�� Belgi�m�� on day �.
RNA preparation. The total RNA of HCC t�mor 
tiss�e sample was extracted by Trizol �Invitrogen 
Life Technologies�� USA��. T�mor tiss�e sample was 
homogenized in � ml of Trizol reagent per ��� mg of 
tiss�e and inc�bated for 5 min at room temperat�re�� 
and then �/5 vol�me of chloroform was added and 
mixed vigoro�sly and inc�bated at room temperat�re 
for 5 min. After centrif�gation at �� ��� × g for �5 min 
at � °C�� the aq�eo�s phase was transferred to a fresh 
t�be�� mixed with an eq�al vol�me of isopropanol�� 
and inc�bated at room temperat�re for 5 min. Total 
RNA was collected and washed in �/5 vol�me of �5% 
ethanol. Total RNA was r�n a denat�ring formaldehyde 
agarose gel to check q�ality. The samples were stored 
at �8� °C before being �sed in electroporation.
RNA electroporation. CD��-B-lymphocytes 
were washed twice with phosphate-b�ffered saline 
�PBS���� res�spended at �.� to �.5 × ��6/��� μl in PBS�� 
and electroporated �� μg RNA/sample; p�lse ��� V�� 
�5� μF��. After electroporation�� fresh complete me-
di�m was added to the cell s�spension and cells were 
inc�bated f�rther at �� °C in a h�midified atmosphere 
s�pplemented with 5% CO�.
Induction of CD8+T-cells with total RNA-elec-
troporated CD40-B-cells. CD��-B-cells�� electropor-
ated with HCC total RNA�� were res�spended in RMPI 
�6�� with ��% FCS. RNA-loaded cells were �sed for 
stim�lation of CD8+T-cells from PBMC �� h after elec-
troporation. Briefly�� ��� × ��5 CD��-B-cells were co-
c�lt�red with � × ��5 the HCC patient’s PBMCs in RMPI 
�6�� s�pplemented with ��% FCS�� � ng/ml IL-� and 
�� ng/ml IL-�. CD��-B-cells were divided into � gro�ps: 
gro�p � �control gro�p — � cells���� gro�p � — ��� cells�� 
gro�p � — ��� cells and gro�p � — ��5 cells. On days � 
and � of the co-c�ltivation�� �� U/ml IL-� was added. On 
day � the level of interferon-γ �IFN-γ�� prod�ced �pon 
restim�lation of the c�lt�red PBMCs was meas�red 
�sing ELISA �BioSo�rce�� Belgi�m�� according to the 
man�fact�rer’s instr�ctions. In addition�� on day � we 
eval�ated CD8 of the PBMCs �sing �FITC��-conj�gated 
anti-CD8 �BD Bioscience�� Belgi�m�� by FCAS.
Autogenic mixed lymphocyte reaction (Auto-
MLR). A�to-PBMCs from the HCC patient were plated 
at � × ��5 cells/well in triplets with � to ��5 irradiated 
��� Gy�� CD��-B electroporated with HCC total RNA 
per well in RPMI-�6�� s�pplemented with ��% FCS. 
Determination of [�H] thymidine incorporation was 
performed in triplicates on days ��days �.
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Cytotoxicity assay. After � days of c�lt�ring�� 
CD8+T-cells ��sing the ��5 cells�� activated with 
total RNA-electroporated CD��-B-cells were 
restim�lated with HCC primary c�lt�red cells. Then the 
vitality of HCC cells was determined by MTT �Sigma�� on 
�� h�� �8 h and �� h. 
Statistical analysis. Res�lts are expressed as 
mean ± S.E.M. Comparisons were validated �sing a 
two-sided St�dent’s t-test. P-val�e < �.�5 was con-
sidered to be statistically significant.
RESULTS
Expansion of CD40-B-cells. CD��-activated 
B -cells are easily expandable and show distinct co-stim-
�latory potential. Intially�� when PBMCs were stim�lated 
with sCD��L�� T-cells and monocytes were inhibited by 
CsA and IL-�. Then B-cells grew well and formed large 
clones with higher cloning efficiency. The cells grow in 
a s�spending stat�s�� and there is none prot�berances 
on the s�rface of the cells. The proliferating cells show 
a typical lymphocyte’s morphological characteristics 
�Fig. ���.
Fig. 1. Expansion of CD��-B-cells on Day ��. At the beginning 
of sCD��L stim�lated to PBMCs�� T-cells and monocytes were 
inhibited by CsA and IL-�. Then B-cells grew well and formed 
large clones with higher cloning efficiency. The Fig�re shows 
CD��-B-cells
Immunophenotyping of CD40-activated 
B-cells. CD��-activated B-cells can be obtained after 
� days of c�ltivation. These cells were highly activated 
as shown by comparable levels of costim�latory mol-
ec�les of CD8� and CD86 �Fig. ���. The expression of 
these molec�les remained stable thereafter. Pheno-
typical analysis of the c�lt�red CD��-B-cells showed 
highly activated expression of CD8� and CD86 on 
s�rface of �nstim�lated B-cells; however�� as it was 
fo�nd�� PBMC did not express high levels of these acti-
vation markers. The high expression of co-stim�latory 
molec�les on CD��-B-cells compared to naive B-cells 
s�ggests that these CD��-B-cells can play the role of 
potent antigen-presenting cells �APCs�� in the activa-
tion and costim�lation of T-cells.
CD40L can up-regulate B-cells to generate 
IL-12. On day �� of CD��L stim�lated PBMCs c�lt�ring�� 
the level of IL-�� was determined by ELISA. The res�lt 
showed that CD��-B-cells can ind�ce B-cells to gener-
ate IL-�� and this effect is dose dependent �Fig. ���. The 
levels of IL-�� were ��.5�5 ± �.58� pg/ml �control gro�p�� 
and ��.��� ± �.�5� pg/ml �experimental gro�p��.
Fig. 2. The variety of CD8� and CD86 of PBMCs stim�lated by 
CD��L. Representative dot plots of PE staining are shown. The 
left part contains the CD8�- or CD86- pop�lation. The right part 
contains the CD8�+ or CD86+ pop�lation. The expression of 
CD8� is �.��% ��d���� �.��% ���d�� and ��.��% ���d��. The expres-
sion of CD86 is �.5�% ��d���� ��.�8% ���d�� and �8.8�% ���d��
Fig. 3. Generation of IL-�� by CD��L ind�ced B-cell. 
The levels of IL-�� were determined by ELISA. The res�lts 
are presented as mean ± S.E.M with triplicate meas�rement. 
*P < �.�5 vs. control.
CD40-B-cell can increase the number of T-cell. 
After � days in c�lt�re the high CD8 expression on 
T-cells stim�lated by electroporated with HCC total RNA 
CD��-B-cells was observed �Fig. ���. The n�mber of CD8+ 
T-cells in PBMCs was 8.�6%. F�rthermore�� RNA-electro-
porated CD��-B-cells positively infl�enced the n�mber of 
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T-cells from PBMCs. In the days ��� ��� 5�� 6 and ��� the viability 
of T-cells increased grad�ally and the q�antity of T-cells 
increased along with the B-cells n�mber �Fig. 5��.
Fig. 4. The variety of CD8 of PBMCs stim�lated by RNA-loaded 
CD��-B-cells. Representative dot plots of FITC staining are 
shown. The left part contains the CD8- pop�lation. The right part 
contains the CD8+ pop�lation. The expression of CD8 is �.��% 
�� d�� and 8.�6% �� d��
CD40-B-cells can induce CD8+ T-cells to gen-
erate IFN-γ. After � days of c�lt�ring�� electroporated 
with HCC total RNA CD��-B-cells stim�lated T-cells 
to prod�ce IFN-γ the levels of which were determined 
by ELISA. The res�lt showed that CD��-B-cells can 
ind�ce CD8+ T-cells to generate IFN-γ and that there 
is a dose dependent effect as well �Fig. 6��. The q�an-
tity of IFN-γ was �.�86 ± �.�58 ng/ml �control gro�p���� 
�.��� ± �.�8� ng/ml ���� cells���� �.��� ± �.��� ng/ml 
���� cells�� and �.658 ± �.��� ng/mL ���5 cells��.
Fig. 5. CD��-B-cells electroporated with HCC total RNA in-
creased the n�mber of T-cells from PBMCs. The cell viability was 
determined by A�to-mixed lymphocyte reaction �A�to-MLR��. The 
res�lts are presented as mean ± S.E.M. with triplicate meas�re-
ment. *P < �.�5 vs. control�� **P < �.�� vs. control.
Fig. 6. CD��-B-cells electroporated with HCC total RNA ind�ced 
CD8+ T-cells to generate IFN-γ. The levels of IFN-γ were determined 
by ELISA. The res�lts are presented as mean ± S.E.M. with triplicate 
meas�rement. *P < �.�5 vs. control�� **P < �.�� vs. control.
T-cells activated with CD40-B-cells can de-
crease the number of HCC cells. The killing effect 
of T-cells was determined by MTT �Fig. ���. After �� h�� 
�8 h and �� h T-cells action�� the vitality of HCC cells 
show significant decrease.
Fig. 7. T-cells activated by CD��-B-cells decreased the n�mber 
of HCC cells. The killing effect of T-cell was determined by MTT. 
The res�lts are presented as mean ± S.E.M. with triplicate mea-
s�rement. *P < �.�5 vs. control�� **P < �.�� vs. control.
DISCUSSION
Earl ier  st�dies have already shown that 
CD��-expanded B-cells can be loaded with antigens 
by means of peptide p�lsing or retroviral transd�ction 
[�5�� �6]. O�r present findings not only indicate that 
CD��-B-cells are to be considered as a highly acti-
vated cell pop�lation with distinct imm�nophenotype 
characteristics�� b�t also that these cells can be loaded 
with RNA antigen by electroporation.
CD8� and CD86 both are type � transmembrane 
proteins with a membrane distal IgV and a membrane 
proximal IgC domain. They share abo�t �5% seq�ence 
homology and interact with the same receptors�� CD�8 
and CTLA-�. The str�ct�ral mechanism of CD8�/CD86 
mediated T-cell costim�lation is not completely �nder-
stood and even less is known abo�t the significance 
of the �niq�e feat�res of CD8� and CD86. To address 
these iss�es�� a n�mber of biochemical�� str�ct�ral and 
biophysical st�dies have been performed [�����]. 
Notably�� str�ct�ral and cell based fl�orescence reso-
nance energy transfer �FRET�� st�dies have demon-
strated that CD8� and CD86 differ in their cell s�rface 
organization and s�ggest that these differences may 
play a key role in T-cell activation [��]. F�rthermore�� 
CD8� and CD86 have been implicated as signaling 
molec�les in B-cell and DCs [�����]. Intrig�ingly�� sig-
naling via CD8� and CD86 in DCs was fo�nd to involve 
the expression of both CD8� and CD86�� s�ggesting 
that the homooligomeric and hetero-oligomeric states 
may be important for APC f�nction [���� �5]. 
IL-�� is recently identified as inflammatory cyto-
kine prod�ced mainly by T- and B-lymphocytes and 
monocytes. It promotes the prod�ction of IFN-γ by 
T-lymphocytes and is necessary for differentiation of 
Th naive cells to Th�-cells [�6]. Mescher et al. [��] 
have proposed that in addition to receiving signals 
by antigen and costim�latory receptors�� naive CD8+ 
T-cells req�ire a ‘third’ signal by IL-�� or type I IFN 
�IFN-I�� comprising IFN-α and IFN-β�� for optimal pro-
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liferation and effector f�nctions. The molec�lar events 
that control this third signal are not clear to date�� b�t 
recent evidence s�ggested that whereas antigen and 
costim�latory signals were s�fficient for �p-reg�la-
tion of the anti-apoptotic proteins Bcl-� and Bcl-xL�� 
IL-�� was needed for Bcl-� �p-reg�lation [�8�� ��]. 
CD8+ T-cells primed in vitro in the presence of IL-�� 
were shown to confer better in vivo protection against 
vir�s challenge [��]. Therefore in the st�dy we inves-
tigated the expression of CD8�/CD86 on the s�rface 
of the CD��-B-cells and the level of IL-�� generated 
by B-cells for exploring the activation of B-cells after 
CD��L stim�lated. The res�lt s�ggests that CD��L can 
stim�late B-cells activated and increase the expression 
of co-stim�latory molec�les on the B-cell s�rface and 
�p-reg�late IL-�� secretion.
Pilot st�dies on DCs-based imm�notherapy have 
ind�ced specific anti-t�mor responses�� incl�ding some 
clinical responses [���� ��]. B�t effective TSA or TAA is 
not identified in a large n�mber of cancers�� altho�gh a 
n�mber of t�mor antigens recognized by CD8+ CTLs 
have been identified [��]. F�rthermore�� it is clear that 
imm�notherapy targeting to a �niq�e antigen have se-
lectively lost the ability to present the defined antigen 
effectively beca�se of changing of t�mor cells feat�res 
[��]. Zhang et al. [�5] find that total t�mor RNA trans-
fected DCs might be an attractive strategy to generate 
t�mor-specific T-cells to treat patients s�ffering from 
HCC. Other st�dies target B-cells s�bstit�te for DCs 
[�6�� ��]. These res�lts �nderscore that CD��-B-cells 
can act as alternative APC for the ex vivo ind�ction of 
T-cell imm�ne responses�� as was shown previo�sly 
for mRNA loaded DCs [�8�� ��]. RNA-loaded APC form 
an excellent tool for f�t�re vaccination strategies�� as 
RNA-based loading of APC overcomes the problem of 
HLA restriction�� which limits the �se of peptide p�ls-
ing. Thro�gh RNA electroporation�� APC can be loaded 
with the f�ll-length antigen�� enabling presentation of 
m�ltiple epitopes witho�t the need for prior charac-
terization of imm�nogenic epitopes. This approach 
also minimizes the risk for generation of t�mor antigen 
loss variants or vir�s escape variants. Moreover�� RNA 
electroporation is a more feasible and safe method to 
apply in a clinical setting compared to �sing viral vec-
tors for transfection of antigens into APC. 
In concl�sion�� o�r res�lts demonstrate that RNA 
electroporation of CD��-B-cells lead to effective 
CD8+ T-cell activation. CD��-B-cells offer many ad-
vantages over monocyte-derived DCs�� we strongly 
believe that this type of approach co�ld conceivably 
be applied to a wide range of cancers for which t�mor-
associated antigens have not been identified.
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CD40-������� ��������������� �-���������   
����СФ��Ц���������� ��� ������� ���П���Ц����Ю�Я���Й 
���Ц���М��� ����УЦ��УЮ� ������ CD8+ T-������� EX VIVO  
Поскольку дендритные клетки (ДК) составляют только 0,1–0,5% мононуклеаров периферической крови (МПК) человека, и 
получение ДК из моноцитов и стволовых кроветворных клеток является трудоемкой и дорогостоящей процедурой, выбраны 
В-лимфоциты в качестве альтернативного источника антигенпрезентирующих клеток (АПК). Цель: изучить возможность 
активированных CD40-лигандом В-лимфоцитов (CD40-B), трансфецированных суммарной ��К, выделенной из клеток         
гепатоцеллюлярной карциномы, индуцировать специфический ответ цитотоксических Т-лимфоцитов ex vivo�  Методы: МПК 
пациентов с гепатоцеллюлярной карциномой изолировали на градиенте фиколла и культивировали в среде RMPI 1640 с   
10% эмбриональной сыворотки телят (ЭСТ), sCD40L (2 мкг/мл) и рекомбинантным человеческим интерлейкином-4 (��-4,        
4 нг/мл). Экспрессию СD80 и CD86 оценивали на проточном цитофлюориметре. Концентрацию интерлейкина-12, проду-         
цируемого культивируемыми В-лимфоцитами, оценивали с помощью иммуноферментного анализа (�ФА). Т-лимфоциты 
получали из МПК пациентов с гепатоцеллюлярной карциномой и культивировали в среде RMPI 1640 с 10% ЭСТ, 2 нг/мл       
��-4 и 10 нг/мл ��-7 и культивированы совместно с CD40-B клетками, трансфецированными опухолевой ��К, для      
индукции пролиферации специфических цитотоксических Т-лимфоцитов. Уровень интерферона-γ (��Ф-γ) определяли с    
помощью �ФА, а экспрессию CD8 �� на проточном цитофлуориметре. Специфическую цитотоксичность оценивали в МТТ          
тесте. Результаты: показано, что активированные in vitro  В-лимфоциты формируют большие колонии, на поверхности 
клеток отмечается высокая экспрессия антигенов CD80/CD86, и ими в повышенных количествах секретируется ��-12.        
CD40-B-лимфоциты, трансфецированные опухолевой ��К, могут активировать CD8      + цитотоксические лимфоциты, ко-
торые продуцируют ��Ф-γ. Выводы: CD40-B-клетки, трансфецированные суммарной ��К, выделенной из опухолевых       
клеток больных с гепатоцеллюлярной карциномой, �� это альтернативные АПК для индукции антигенспецифического CD8+ 
T-клеточного ответа, что может быть использовано для иммунотерапии пациентов с гепатоцеллюлярной карциномой.            
Ключевые слова: CD40L, B-лимфоциты, антигенпрезентирующие клетки, иммунотерапия, гепатоцеллюлярная карцинома.      
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